;
Skip to main content
Home > SciBX > Translational Notes

Chronological Index of : Translational Notes

 Current Issue
  • Translational tidbits

    The Cancer Prevention & Research Institute of Texas is back in the grant-making business, GlaxoSmithKline picks academic projects for drug screening collaborations, and a roundup of public-private partnerships.

    Published on 11/7/2013
  • Table 1: Selected public-private partnerships for October 2013

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for October 2013. Two significant developments in the public-private partnership space this month include the launch of Tri-…

    Published on 11/7/2013
  • Figure 1: Preclinical and clinical studies that drove CAR-based T cell therapeutic development

    Translational Notes: Driving CAR-based cellular therapies Figure 1. Preclinical and clinical studies that drove CAR-based T cell therapeutic development. About 20 years of cumulative work in academic centers has …

    Published on 10/24/2013
  • Table 1: Selected deals and partnerships in the adoptive T cell immunotherapeutic space from 2008 onward

    Translational Notes: Driving CAR-based cellular therapies Table 1. Selected deals and partnerships in the adoptive T cell immunotherapeutic space from 2008 onward. The August 2012 deal between Novartis AG and the …

    Published on 10/24/2013
  • Figure 1: Dopamine departure

    Translational Notes: Synaptic synopsis Figure 1. Dopamine departure. Compounds in disclosed company-sponsored programs. Source: BCIQ: BioCentury Online Intelligence

    Published on 10/24/2013
  • Table 1: Glutamate mates

    Translational Notes: Synaptic synopsis Table 1. Glutamate mates. Compounds in development for autism spectrum disorders (ASD), schizophrenia and depression. Target Company Product Development stage Indication …

    Published on 10/24/2013
  • Driving CAR-based cellular therapies

    Adoptive T cell therapies recently entered the limelight owing to dramatic clinical results achieved with their latest incarnation, chimeric antigen receptor-based cell therapies. Novartis' 2012 CAR deal with the …

    Published on 10/24/2013
  • Synaptic synopsis

    The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Genetic findings …

    Published on 10/24/2013
  • Table 1: Selected recent deals and partnerships in the epigenetics space

    Translational Notes: Clinical takeoff for new epigenetic targets Table 1. Selected recent deals and partnerships in the epigenetics space. The January 2012 deal between the Genentech Inc. unit of Roche and …

    Published on 10/17/2013
  • Table 2: Selected clinical stage compounds that target epigenetic regulators

    Translational Notes: Clinical takeoff for new epigenetic targets Table 2. Selected clinical stage compounds that target epigenetic regulators. The availability of new research tools and data on epigenetic regulators …

    Published on 10/17/2013
  • Clinical takeoff for new epigenetic targets

    Next year is expected to be a banner year for next-generation epigenetics companies, with key clinical data expected for next-generation drugs and first-generation candidates. Big biotech and pharma companies that …

    Published on 10/17/2013
  • Translational tidbits

    The NIH's BRAIN initiative has unveiled its near-term research priorities; research tool suppliers are starting to place bets on CRISPR-Cas9-based genome editing; a roundup of public-private partnerships shows multiple …

    Published on 10/10/2013
  • Table 1: Selected public-private partnerships for September 2013

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for September 2013. After a quiet August, public-private partnership activity surged in September. Significant developments …

    Published on 10/10/2013
  • Advancing AD

    The NIH has made a trio of grants to academics to develop a systems biology picture of Alzheimer's disease. The teams hope to uncover new mechanisms and targets that may have been overlooked because of the field's …

    Published on 10/3/2013
  • The Broad's outlook in cancer

    When the Broad Institute launched its Center for the Science of Therapeutics to develop new therapies, it lacked funds to take discoveries all the way to approval. A new collaboration with Bayer fills that gap for …

    Published on 10/3/2013
  • Collaborating against diabetes complications

    Pfizer's deal with the Sanford-Burnham Medical Research Institute to identify and validate new drug targets to prevent and treat insulin resistance and organ damage in obesity-related diabetes could help reverse a trend…

    Published on 8/29/2013
  • Found in translation: Institute Pasteur Korea

    Institute Pasteur Korea is starting to see translatable results from its deal-making and drug screening efforts. After signing a pair of infectious disease discovery deals with Sanofi and Roche this year, the institute …

    Published on 8/22/2013
  • Translational tidbits

    The Scripps Research Institute has teamed up with Sigma-Aldrich to fast-track access to reagents emerging from Scripps labs; TTOs grapple with recent patent rulings; and a roundup of July's public-private partnerships …

    Published on 8/15/2013
  • Table 1: Selected public-private partnerships for July 2013

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for July 2013. (continued) Companies Institutions Business area Disclosed value Purpose Table 1. Selected public-private …

    Published on 8/15/2013
  • MJFF's progress in markers

    To identify clinical populations for testing new therapies for Parkinson's disease, the Michael J. Fox Foundation made available the first set of data and samples from its LRRK2 Cohort Consortium and presented …

    Published on 7/25/2013
  • GSK and UC make up

    GlaxoSmithKline and the University of California have reconciled their differences over whether researchers at the 10-campus system can participate in GSK's Discovery Fast Track program. The UC technology transfer …

    Published on 7/18/2013
  • Translational tidbits

    Last month's public-private partnership with the highest total funding was the launch of the Global Health Innovative Technology Fund, a $100 million infectious disease initiative. On the biotech side, Onyx formed an …

    Published on 7/11/2013
  • Table 1: Selected public-private partnerships for June 2013

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for June 2013. Significant public-private partnerships announced in June included the NIH's National Center for Advancing …

    Published on 7/11/2013
  • Table 1: NCATS's first repurposing round

    NCATS's nine lives Table 1. NCATS's first repurposing round. Source (unless otherwise noted): BCIQ: BioCentury Online Intelligence; National Center for Advancing Translational Science (NCATS). Company Academic …

    Published on 6/27/2013
  • NCATS's nine lives

    The NIH's National Center for Advancing Translational Sciences has awarded a total of $12.7 million to 9 academic research groups to repurpose compounds from 5 pharma partners in the center's Discovering New Therapeutic…

    Published on 6/27/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993